Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
FT113
Cat. No.:
OB0225LY-0015
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
FT113 is a novel and potent inhibitor of fatty acid synthase (FASN), which has demonstrated anti-cancer activity, making it a promising candidate for cancer research.
Synonym:
1630808-89-7; (4-(4-(6-Fluorobenzo[d]oxazol-2-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone; [4-(6-Fluoro-1,3-benzoxazol-2-yl)phenyl]-[4-(1-hydroxycyclopropanecarbonyl)piperazin-1-yl]methanone; 1-{4-[4-(6-Fluoro-1,3-benzoxazol-2-yl)benzoyl]piperazine-1-carbonyl}cyclopropan-1-ol
CAS No.:
1630808-89-7
Compound CID:
118621601
Formula:
C22H20FN3O4
Formula Weight:
409.41
Specification
Relative Density:
1.456 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
FT113 is a novel compound targeting the acetyl-CoA synthetase family, involved in cellular energy metabolism, with potential applications in metabolic disorders and cancer.
Library Information
Targets:
Fatty acid synthesis
Receptors:
FAS; Fatty acid synthase
Pathways:
Metabolism
Plate Number:
AOCL-1
Plate Location:
b6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
62.5 mg/mL; 152.66 mM
